Use of Low-Molecular-Weight Heparin and Peak anti-Xa Monitoring In Severe SARS-CoV-2 Disease: A Brief Report

Use of Low-Molecular-Weight Heparin and Peak anti-Xa Monitoring In Severe SARS-CoV-2 Disease: A Brief Report

In 2019, a novel coronavirus was identified in Wuhan, China. This strain was classified as a pandemic in early 2020 by the World Health Organization (WHO), rapidly reaching millions of cases worldwide and overwhelming intensive care units. One distinct feature identified in severe SARS-CoV-2 is abno...

Full description

Bibliographic Details
Main Authors: Drexler, N. (Author), Fatteh, N. (Author), Lozada, J. (Author), Toor, R. (Author), Zamora, F.J (Author)
Format: Article
Language:English
Published: SAGE Publications Ltd 2021
Subjects:
acute kidney failure
adult
anticoagulant therapy
anticoagulation
antiviral therapy
Article
azithromycin
blood clotting factor 10a
breathing rate
C reactive protein
case report
clinical article
comorbidity
coronavirus disease 2019
coughing
critically ill patient
D dimer
D-dimer
deterioration
do not resuscitate order
drug withdrawal
dyspnea
echocardiography
enoxaparin
extubation
fatality
ferritin
fever
fibrin
fibrinogen
ground glass opacity
heparin
high flow nasal cannula therapy
Hispanic
Horowitz index
hospital discharge
human
hydrocortisone
hydroxychloroquine
hypercoagulability
hypertensive factor
hypoxemia
Indonesian
intensive care unit
international normalized ratio
intubation
lung infiltrate
malaise
male
melena
methylprednisolone
middle aged
monitoring
multidisciplinary team
neuromuscular blocking
nitric oxide
oxygen saturation
oxygen therapy
partial thromboplastin time
peak anti-Xa level
prone position
SARS-COV-2
severe
Severe acute respiratory syndrome coronavirus 2
ship
tachypnea
thorax radiography
thromboelastography
thromboembolism
thrombosis prevention
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items